Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BUZZARD: Brolucizumab vs Aflibercept in Diabetic Macular Edema
NCT04079231Phase 3Withdrawn
- Sponsor
- Novartis
- Start
- Feb 2021
- Primary completion
- Jan 2023
- Modality
- scFv Fragments, Monoclonal Antibodies
01
Overview
A Phase 3 trial of brolucizumab in diabetic macular edema (DME), sponsored by Novartis. Planned start Feb 2021; status: withdrawn.
02
Drugs
brolucizumab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT04079231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04079231.